This method is of particular importance in light of the recent findings suggesting that adoptive T-cell therapies (e.g., mesothelin-specific CAR-modified T cells and NY-ESO-1-specific TCR-engineered T cells) are capable of epitope spreading.30,31 It is hypothesized that tumor lysis and inflammation induced by CAR T cells seem to result in the release of tumor antigens that are presented by dendritic cells to T cells resulting in the activation and expansion of endogenous T-cell clones. Here, MSLN is linked to neoplasm.